FDA Advisory Panel Recommends Careful Scrutiny Of Adverse Events With Leadless Pacemakers
This article was originally published in Clinica
Executive Summary
The US FDA should require manufacturers of leadless pacemakers to sponsor long post-market studies of these devices and track each type of adverse event separately.